John Simard, a significant shareholder in XBiotech Inc., has recently acquired an additional 70,000 shares of the company. This transaction, reported on November 13, 2026, marks a notable increase in his ownership stake, bringing his total holdings to approximately 4.26 million shares. The acquisition is significant as it reflects Simard's confidence in XBiotech's future prospects in the pharmaceutical industry.

Background

XBiotech Inc. is a biotechnology company focused on developing innovative treatments for various diseases. The company is categorized under the Pharmaceutical Preparations sector. Simard has been actively involved in the company's ownership, as indicated by his recent filings with the SEC.

What the Filing Says

According to the SEC filing (accession number 0001193125-26-460514), Simard's transaction occurred on November 3, 2026, at a price of $2.0487 per share. Following this transaction, he now owns a total of 4,261,690 shares in XBiotech.

Impact

This acquisition may have several implications for XBiotech and its stakeholders. As a director and significant owner, Simard's actions could influence investor sentiment and confidence in the company's direction. His increased stake may also indicate a positive outlook on the company's upcoming projects and developments.

What's Next

The filing does not say what happens next.

Ownership Details

John Simard is not only a significant shareholder but also serves as a director of XBiotech Inc., which further emphasizes his commitment to the company's governance and strategic direction. His direct ownership of 4,261,690 shares represents more than 10% of the company's total shares, solidifying his status as a key stakeholder.

Company Information

XBiotech Inc. is incorporated in the state of Texas and operates within the Pharmaceutical Preparations sector, specifically under the Standard Industrial Classification (SIC) code 2834. The company is headquartered at 5217 Winnebago Lane, Austin, TX, and can be reached at the business phone number 512-386-2900.

Transaction Specifics

The transaction was executed on November 3, 2026, under the SEC Form 4, which is used to report changes in the ownership of a company's securities by its insiders. Simard's acquisition of 70,000 shares at a price of $2.0487 per share indicates a direct ownership nature, as noted in the filing. This transaction is classified as an acquisition (code 'A') under the SEC's transaction coding system.

Filing Context

The filing was officially submitted to the SEC on November 13, 2026, reflecting the regulatory requirements for timely disclosure of insider transactions. The accession number for this filing is 0001193125-26-460514, which can be referenced for further details on the transaction.